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Abstract
Background and purpose—To study whether cytokine markers may improve predictive 
accuracy of radiation esophagitis (RE) in non-small cell lung cancer (NSCLC) patients.
Materials and methods—A total of 129 patients with stage I-III NSCLC treated with 
radiotherapy (RT) from prospective studies were included. Thirty inflammatory cytokines were 
measured in platelet-poor plasma samples. Logistic regression was performed to evaluate the risk 
factors of RE. Stepwise Akaike information criterion (AIC) and likelihood ratio test were used to 
assess model predictions.
Results—Forty-nine of 129 patients (38.0%) developed grade ≥2 RE. Univariate analysis showed 
that age, stage, concurrent chemotherapy, and eight dosimetric parameters were significantly 
associated with grade ≥2 RE (p < 0.05). IL-4, IL-5, IL-8, IL-13, IL-15, IL-1α, TGFα and eotaxin 
were also associated with grade ≥2 RE (p <0.1). Age, esophagus generalized equivalent uniform 
dose (EUD), and baseline IL-8 were independently associated grade ≥2 RE. The combination of 
these three factors had significantly higher predictive power than any single factor alone. Addition 
of IL-8 to toxicity model significantly improves RE predictive accuracy (p = 0.019).
Conclusions—Combining baseline level of IL-8, age and esophagus EUD may predict RE more 
accurately. Refinement of this model with larger sample sizes and validation from multicenter 
database are warranted.
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Radiation esophagitis (RE) is a common acute toxicity for non-small cell lung cancer 
(NSCLC) patients treated with radiation therapy (RT). It occurs during RT and often persists 
for several weeks after completion of RT. Grade ≥2 RE developed in about 50% of patients 
[1], which is clinically significant and may compromise the treatment result due to medical 
intervention or sometimes a treatment break. Identification of predictive factors for RE 
facilitates safe delivery of optimal prescribed dose to an individual patient. A meta-analysis 
published in 2013 [1] showed that V60 of esophagus provides the best predictive ability for 
RE among all clinical and dosimetric factors, although clinical stage, nodal stage, 
performance status, type of chemotherapy, RT schedule (total number of fractions, dose per 
fraction) are statistically predictive of RE.
Risk of RE in each individual patient is often not explained by these clinical factors. In 
clinical practice, patients with similar clinical factors and dose volume distributions to the 
esophagus commonly have different risks of RE. Additional biomarkers reflecting inherent 
radiosensitivity of esophagus might improve the predictive potential, including single 
nucleotide polymorphisms (SNPs) in the TGFβ1 gene [2–4], certain serum miRNA [5], or 
certain genetic parameters [6]. Currently, no reliable biomarker has been found that can be 
used in clinic as early predictors of RE.
Our hypothesis is (1) baseline levels of inflammatory cytokines, or their dynamic changes 
during RT, correlate with the risk of RE; and (2) the addition of inflammatory cytokines to 
other dosimetric and clinical factors improves the prediction of RE.
Methods
The study population included 129 patients with newly diagnosed stage I–III NSCLC, 
consecutively enrolled in 3 prospective Institutional Review Board-approved NSCLC studies 
conducted at the University of Michigan Cancer Center and the Veterans Affairs Medical 
Center, Ann Arbor, MI: (1) a phase 1/2 study of RT dose escalation (limited to a lung normal 
tissue complication probability [NTCP] value of <15%) with concurrent chemotherapy and 
2 consecutive studies using (2) functional imaging and (3) biomarkers to assess outcome 
(ClinicalTrials.gov: NCT01190527, NCT00603057).
All patients received definitive radiotherapy. Radiotherapy was delivered using three-
dimensional conformal technique. A median total dose of 70 Gy (range, 44–85.5 Gy) was 
administered in 2.0–2.9 Gy daily fractions over 4–7 weeks using 6 or 6/16 MV photons. The 
prescribed dose covered 95% planning target volume (PTV). In patients treated under dose 
escalated protocols, the effective volume of esophagus irradiated (Veff) computed with a 
normalization dose biologically equivalent to 72 Gy in 2 Gy fractions was limited to less 
than 1/3 of the esophagus.
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On planning CT, the esophagus was defined to include the esophageal wall and lumen which 
was contoured from cricoid to gastroesophageal junction for dosimetric computation. Dose–
volume histograms (DVH) for the esophagus were then calculated after conversion of doses 
to their 2 Gy equivalents (EQD2) using the linear quadratic model with alpha/beta of 10. 
The following dosimetric parameters of esophagus were retrieved or converted from the 
DVH: The total volume of esophagus (Vtotal); the maximum dose (Dmax); the mean dose 
(Dmean); the relative volume of esophagus receiving >60 Gy (rV60); the absolute volume of 
esophagus which received >60 Gy (aV60), and >70 Gy (aV70); generalized equivalent 
uniform dose (EUD) and NTCP. Lyman model parameters (TD50 = 68 Gy, n = 1/a = 0.06, m 
= 0.11) were used to compute EUD and NTCP [7].
All patients were evaluated prospectively weekly during RT, with follow-up evaluations at 1 
month after completion of RT, every 3 months for 1 year, every 6 months at second year and 
yearly afterward. At each follow-up, patients underwent a history review and physical 
examination as well as a chest CT scan. Treatment-related toxicity including RE was 
evaluated and graded at the time of visit by the treating physician according to Common 
Terminology Criteria for Adverse Events version 3.0. The maximum esophagitis grade was 
recorded for each patient. The incidence of RE was calculated as the number of patients with 
RE divided by the total number of patients. The primary endpoint in this study was grade ≥2 
RE, including dysphagia and odynophagia.
Serial blood samples were collected with K2EDTA (dikalium salt of 
ethylenediaminetetraacetic acid) anticoagulant within two weeks prior to RT (pre) and at 2 
weeks (2w) and 4 weeks (4w) during RT. Blood samples were placed in ice immediately 
after collection, centrifuged within 6 h of collection at 3000 g for 30 min (4°C), and 
supernatants were collected and stored at −80°C until use.
Thirty cytokines related to inflammatory process and with available commercial kits were 
selected for this study. Measurements of cytokines were performed in these platelet-poor 
plasma samples. Commercial Human Cytokine/Chemokine Magnetic Bead Panel kits 
(MILLIPLEX® MAP, Cat. # HCYTMAG-60K-PX29 (pre-mixed); Millipore, Billerica, MA) 
were used to measure the levels of 29 cytokines, including EGF, Eotaxin, Fractalkine, G-
CSF, GM-CSF, IFNγ, IL-10, IL-12P40, IL-12P70, IL-13, IL-15, IL-17, IL-1RA, IL-1α, 
IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MIP-1α, MIP-1β, sCD40L, TGF-α, 
TNFα, VEGF. TGF-β1 level was measured by molecule-specific enzyme-linked 
immunosorbent assay (Human TGFβ1 DuoSet kit, R&D Systems Inc., Minneapolis, MN). 
All sample tests were run in duplicate, according to the manufacturer’s instructions.
Univariate logistic regression was performed with Grade 2 or more RE as a dependent 
variable to determine potential predictors of RE, including clinical factors, dosimetric 
parameters, and cytokine levels (pre, 2w, 4w) and ratios at 2 and 4 weeks to baseline (2w/pre 
and 4w/pre). All cytokine levels were log-transformed for use in the logistic regression 
models because of their skewed distribution. All significant factors were considered for a 
multivariate model based upon their significance in univariate regression. Factors were 
selected using a forward stepwise selection procedure based upon the Akaike information 
criterion (AIC) as well as the likelihood ratio test (LRT). Because of the high degree of 
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correlation between dosimetric measures, one dosimetric variable was selected by evaluating 
both the p-value and AIC for univariate models with dosimetric factors. The combined 
model was also compared with univariate models comparing AUC of each model’s Receiver 
operating characteristic (ROC) curve from the data. Cutoff points were created for age, 
EUD, and baseline cytokine like IL-8 based on maximum values of the sum of sensitivity 
and specificity. All p-values were from two-sided test.
Results
Table 1 shows the baseline clinical characteristics. The median age of the 129 patients was 
66 years (range, 40–92 years) with ECOG performance status 0–2. All patients received 
definitive RT with or without concurrent chemotherapy. Carboplatin and paclitaxel were 
used as concurrent chemotherapy regimen in 88% of patients.
Forty out of 129 patients (31.0%) developed grade 1 RE, 33 patients (25.6%) grade 2, 15 
patients (11.6%) grade 3, and one patient (0.8%) grade 4. There were no esophagitis-related 
deaths. Altogether, 49 patients (38.0%) had grade ≥2 RE. The median time from the start of 
RT to the development of grade ≥2 RE was 4.0 weeks (range; 1–20 weeks). It was 3.0 weeks 
(range; 1–18 weeks) for grade 2 RE and 4.5 weeks (range; 2–20 weeks) for grade 3–4 RE.
Age, gender, smoking history, stage, RT dose and concurrent chemotherapy were evaluated 
for the association with RE, with age and RT dose as continuous variables. Younger age 
(OR: 0.94, 95% CI: 0.91–0.98; p = 0.003), stage III disease (OR: 4.70, 95% CI: 1.00–21.70; 
p = 0.048), use of concurrent chemotherapy (OR: 4.13, 95% CI: 1.45–11.70; p = 0.010) 
were significantly associated with higher risk of grade ≥2 RE.
One hundred and three patients had dosimetric parameters of esophagus available. Higher 
NTCP, Dmax, Dmean, EUD, rV60, aV60, aV70 were associated with higher risk of grade 
≥2 RE (Table 2). These dosimetric parameters were all significantly correlated with each 
other (p < 0.001).
TGF-β1 was measured before RT in 129, at 2w in 128, and at 4w in 107 patients. The other 
29 cytokines were measured before RT and 2w in 129, at 4w in 127 patients. The association 
of the levels of 30 cytokines with grade ≥2 RE is shown in Table 3. IL-4, IL-5, IL-8, IL-13, 
IL-15, IL-1α, TGFα, TGFβ1 and eotaxin at different time points were associated with grade 
≥2 RE (p < 0.1). Under univariate analysis, baseline levels of IL-8, IL-13 and eotaxin, levels 
at 2w during RT of IL-13, IL-15 and eotaxin, and 2w/pre ratio of eotaxin were significantly 
correlated with grade ≥2 RE (p < 0.05). Patients who developed Grade ≥2 RE had lower pre-
IL-8 levels than those with grade 0–1 RE (Fig. 1 for comparison of means) (see Fig. 2 for 
scatter plot of each individual patient).
Age, esophagus EUD, and baseline IL-8 remained in the final predictive model. The 
Receiver operating characteristic (ROC) curves showed that the AUC increased to 0.78 by 
combining IL-8, EUD and age compared with 0.62 by IL-8, 0.64 by age and 0.70 by EUD 
alone (Fig. 3). The relative predictive ability was significantly higher by combining IL-8, 
EUD and age than that of EUD and age alone (p = 0.019). Cutoff points for age, EUD, and 
baseline IL-8 were 69 years, 41.4 Gy, and 24.8 pg/ml. Rates of Grade ≥2 RE were 14.2% (5 
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of 35), 42% (18 of 43), 70% (14 of 20), and 100% (5 of 5) for 0, 1, 2, and 3 risk factors, 
respectively (p < 0.001).
Discussion
This study demonstrated that age, esophagus EUD, and baseline IL-8 were independent risk 
factors for Grade ≥2 RE. A model including all three factors performed better than models 
based on each separately.
Many studies have investigated the predictors of RE, in which grade ≥2 or ≥3 RE was 
frequently used as the endpoint. The majority of them have focused on dosimetric factors. In 
our previous study, normal tissue complication probability (NTCP) value was the only 
significant dosimetric predictor of RE in multivariate analysis [8]. In the QUANTEC study, 
esophageal volumes receiving >40–50 Gy correlated significantly with acute RE [9]. In 
current study, esophagus NTCP, EUD, Dmean, Dmax, rV60, aV60, aV70 were all 
significantly associated with the risk of RE. This study confirmed significance of all the 
above parameters and demonstrated that EUD remained in the final model to best predict RE 
with AUC of 0.70 by itself. In the literature, different parameters were identified as the most 
predictive factors in different studies, including rV20 [10], V35 [11], V50 [12–14], V55 
[15], V60 [15], Dmean [16], Dmax [16–18]. We confirmed that esophagus dosimetric 
parameters were the most important factors for predicting RE, and limiting the irradiation 
dose to esophagus is the first crucial step to reduce the risk of RE. Since the parameters were 
well correlated, comprehensive dose-volume histogram evaluation is needed.
Clinical factors, such as younger age [17,19,20], pre-RT dysphagia [17], lower pre-RT body 
mass index [12], as well as tumor-factors such as nodal stage of N2 or worse [17], have been 
shown to be correlated with higher risk of RE. Concurrent chemotherapy has been 
consistently shown to correlate with an increased rate of RE [11,15,16,18,21]. However, in 
current study, age was the only independent predictive clinical factor, though stage and 
concurrent chemotherapy were significantly correlated with RE in univariate analysis, as 
these factors were significantly correlated with each other, age outperformed other factors. 
Younger age was associated with higher risk of RE, which might be explained that younger 
patients had increased visceral pain sensation than old ones [22,23].
Though it has been shown that predictive model constructed with dosimetric parameter and 
clinical factors produced good discriminative ability [24], additional biomarkers help to 
explain individual variation in patients’ reactions and further improve the predictive ability 
of RE. In current study, we found IL-8 to be an independent predictor for RE. AUC 
increased to 0.78 by combining IL-8, EUD and age compared with 0.62 by IL-8, 0.64 by age 
and 0.70 by EUD alone. IL-8 also increased the predictive ability with addition to EUD and 
age. Lower baseline IL-8 was associated with higher risk of grade ≥2 RE. To the best 
knowledge of the authors, this finding has not been reported previously. IL-8 is a cytokine of 
the CXC chemokine family, playing a role in neutrophil recruitment and activation. Low 
IL-8 has been reported to be associated with increased risk of radiation-induced lung toxicity 
in NSCLC [25–27] and the need for percutaneous endoscopic gastrostomy (PEG) tube 
installation due to mucositis during RT of head and neck squamous cell cancers [28]. 
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However, two studies showed that there was a correlation between RT-induced normal tissue 
inflammation evaluated by (18)F-fluorodeoxyglucose (FDG) PET and patient outcome. 
Increased FDG uptake in esophagus after RT was significantly associated with better tumor 
response and tumor control in esophageal cancer [29], while increased FDG uptake in 
normal lung and pleura after RT was significantly associated with better tumor response in 
NSCLC [30], suggesting that tumor radioresponsiveness and normal tissue radiosensitivity 
may be linked based on shared genetic determinants of inherent radiosensitivity. The 
immunosuppressive function of IL-8 may lead to decreased side effects but also to worse 
tumor response. IL-8 as a universal anti-inflammatory cytokine and its role in predicting RT-
induced toxicity and tumor response should be further explored.
There are some but not many studies investigating the biomarkers predictive of the risk of 
RE. The acute phase responses (thrombocytosis and anemia) were found to be associated 
with RE [31]. Single nucleotide polymorphisms (SNPs) in the TGFβ1 gene were found to be 
associated with Grade ≥2 or ≥3 RE [2–4] and this finding was validated in one study [3]. 
High serum miR-155 and miR-221 during the first 2 weeks of concurrent 
chemoradiotherapy were found to be associated with the development of severe RE [5]. In a 
model developed by De Ruyck et al., two clinical (nodal stage and gender), four treatment 
(chemotherapy, Dmean of esophagus, overall treatment time, and RT technique), and four 
genetic (rs2302535, rs16930129, rs1131877, and rs2230528) parameters were found to be 
highly predictive for the development of Grade ≥2 RE. The positive predictive value of the 
biomarker is 69.4%, and the negative predictive value is 87.4% [6]. More works need to be 
done in finding consistent and clinically useful biomarkers.
Our study has some limitations. Firstly, the sample size and the number of events were not 
large enough to perform a reliable validation. Secondly, the sample size was also small 
compared to the high number of tested variables being investigated, which prevented 
performance of complicated analyses to illustrate the complex interplay between cytokines. 
Thirdly, there were not enough events to build a model to predict the more clinically 
important endpoint of RE (Grade ≥3).
In conclusion, age, esophagus EUD, and baseline IL-8 were independent predictors of RE in 
patients treated with RT for NSCLC. Addition of IL-8 to toxicity model significantly 
improves RE predictive accuracy. IL-8 as an anti-inflammatory cytokine needs to be 
validated in large patient populations.
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Fig. 1. 
IL-8 levels for patients with and without Grade ≥2 RE. RE = radiation esophagitis; RT = 
radiotherapy.
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Fig. 2. 
Scatted plots of values of pre-IL-8 and EUD of each patient with and without RE. RE = 
radiation esophagitis; EUD = equivalent uniform dose.
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Fig. 3. 
Receiver operating characteristic (ROC) curves of clinical and dosimetric factors (age, 
esophagus EUD) and cytokines (pre-IL-8) for grade ≥2 RE. RE = radiation esophagitis; 
EUD = equivalent uniform dose.
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Table 1
Baseline patient and treatment related characteristics.
Variables N (%)
Gender
Male 100 (77.5)
Female 29 (22.5)
Smoking history
Never or former smoker 59 (45.8)
Current smoker or recently quit 63 (48.8)
Unknown 7 (5.4)
Histology
Adenocarcinoma 25 (19.4)
Squamous carcinoma 47 (36.4)
Poorly differentiated 42 (32.6)
NOS 15 (11.6)
Stage
I–II 15 (11.6)
III 112 (86.8)
Unknown 2 (1.6)
Concurrent chemotherapy
Yes 88 (68.2)
No 31 (24.0)
Unknown 10 (7.8)
Radiation dose (Gy)
44–59 6 (4.6)
60–69 56 (43.4)
70–79 46 (35.7)
80–85.5 21 (16.3)
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Table 2
The distribution of dosimetric parameters of esophagus and their association with grade ≥2 radiation 
esophagitis.
Dosimetric parameter Median (range) OR (95% CI) p-Value
Vtotal (cc) 42.7 (22.3-101.5) 0.49 (0.11, 2.24) 0.359
NTCP(%) 11.0 (0-59.7) 1.55 (1.18, 2.03) 0.002
Dmax (Gy) 70.0(2.6-92.2) 22.85 (1.87, 280.00) 0.014
Dmean (Gy) 26.3 (0.3-54.9) 2.72 (1.17, 6.32) 0.020
EUD (Gy) 58.8 (1.4-69.8) 19.74 (1.88, 207.00) 0.013
Veff (%) 3.5 (0-59.8) 1.60 (1.21-2.12) 0.001
rV60 (%) 15.0 (0-52.3) 1.77 (1.24, 2.53) 0.002
aV60 (cc) 6.1 (0-27.7) 1.83 (1.21, 2.77) 0.004
aV70 (cc) 0.0 (0-17.3) 1.92 (1.19, 3.11) 0.008
Note: NTCP: normal tissue complication probability, EUD: equivalent uniform dose.
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